211 related articles for article (PubMed ID: 28332143)
1. The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA
Kim SR; Lee YH; Kang ES; Cha BS; Lee BW
Diabetes Ther; 2017 Jun; 8(3):601-609. PubMed ID: 28332143
[TBL] [Abstract][Full Text] [Related]
2. Morning Spot Urine Glucose-to-Creatinine Ratios Predict Overnight Urinary Glucose Excretion in Patients With Type 2 Diabetes.
Kim SR; Lee YH; Lee SG; Lee SH; Kang ES; Cha BS; Lee HC; Kim JH; Lee BW
Ann Lab Med; 2017 Jan; 37(1):9-17. PubMed ID: 27834060
[TBL] [Abstract][Full Text] [Related]
3. Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Diabetes Ther; 2020 Apr; 11(4):951-964. PubMed ID: 32166619
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
[TBL] [Abstract][Full Text] [Related]
5. LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2.
Powell DR; Smith MG; Doree DD; Harris AL; Xiong WW; Mseeh F; Wilson A; Gopinathan S; Diaz D; Goodwin NC; Harrison B; Strobel E; Rawlins DB; Carson K; Zambrowicz B; Ding ZM
Pharmacol Res Perspect; 2015 Mar; 3(2):e00129. PubMed ID: 26038705
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Neumiller JJ
Drugs Context; 2014; 3():212262. PubMed ID: 24991224
[TBL] [Abstract][Full Text] [Related]
7. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
[TBL] [Abstract][Full Text] [Related]
8. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor.
Song L; Wang X; Sun J; Hu X; Li H; Hu P; Liu D
Clin Pharmacokinet; 2023 Mar; 62(3):505-518. PubMed ID: 36802026
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
[TBL] [Abstract][Full Text] [Related]
10. Clinical Predictors of the Hypoglycemic Effect of Sodium-Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study.
Hirai T; Kawagoe Y; Kei M; Ogawa R; Itoh T
Biol Pharm Bull; 2020; 43(5):782-787. PubMed ID: 32378557
[TBL] [Abstract][Full Text] [Related]
11. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus.
Jiang A; Feng Z; Yuan L; Zhang Y; Li Q; She Y
Diabetol Metab Syndr; 2021 Mar; 13(1):34. PubMed ID: 33766125
[TBL] [Abstract][Full Text] [Related]
12. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
13. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Cariou B; Charbonnel B
Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
[TBL] [Abstract][Full Text] [Related]
14. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
Yoshimoto T; Furuki T; Kobori H; Miyakawa M; Imachi H; Murao K; Nishiyama A
J Investig Med; 2017 Oct; 65(7):1057-1061. PubMed ID: 28596160
[TBL] [Abstract][Full Text] [Related]
15. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
16. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy and Safety of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors in Real-World Clinical Practice: Potential Cautionary Use in Elderly Patients with Type 2 Diabetes (T2D).
Lee DH; Oh JH; Jeon HJ; Oh TK
Diabetes Ther; 2024 Jul; 15(7):1615-1626. PubMed ID: 38771472
[TBL] [Abstract][Full Text] [Related]
18. Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.
Ito D; Ikuma-Suwa E; Inoue K; Kaneko K; Yanagisawa M; Inukai K; Noda M; Shimada A
J Clin Med Res; 2017 Feb; 9(2):154-162. PubMed ID: 28090231
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.
Bashier A; Khalifa AA; Rashid F; Abdelgadir EI; Al Qaysi AA; Ali R; Eltinay A; Nafach J; Alsayyah F; Alawadi F
J Clin Med Res; 2017 Jun; 9(6):499-507. PubMed ID: 28496550
[TBL] [Abstract][Full Text] [Related]
20. Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial.
Baba Y; Ishibashi R; Takasaki A; Ito C; Watanabe A; Tokita M; Meguro M; Harama T; Hirayama K; Yamamoto T; Nakamura S; Koshizaka M; Maezawa Y; Uchida D; Okajima F
Diabetes Ther; 2021 May; 12(5):1415-1427. PubMed ID: 33738773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
